











# LEO Pharma pipeline overview

## 2020 Q3

Project*	Description	Partners	Pre-clinical	Phase 1	Phase 2	Phase 3	Registration
<b>DERMATOLOGY</b>							
<b>Tralokinumab</b> LP0162	An IL-13 anti-inflammatory monoclonal antibody under development for atopic dermatitis.	AstraZeneca 					
<b>Delgocitinib</b> LP0133	A topical pan-JAK inhibitor under development for chronic hand eczema and atopic dermatitis.	JT 					
<b>Anti IgE<sup>+</sup>B-cell</b> LP0201	A monoclonal antibody under development for atopic dermatitis and allergic asthma.	ONENESS BIO  MICROBIO 					
<b>Anti IL-22R</b> LP0145	An anti-inflammatory monoclonal antibody under development for atopic dermatitis.	argenx 					
<b>H4R antagonist</b> LP0190	A systemic anti-pruritic and anti-inflammatory H4 receptor antagonist under development for atopic dermatitis.	JW 					
<b>IL-17A PPI</b> LP0200	An IL-17 small-molecule modulator under development for psoriasis.						

\*Project compounds in our pipeline are investigational only and have not been approved by any regulatory authority.

